Manufacturer reports data from ADVANCE and MOTIVATE Phase 3 studies for use of risankizumab (Skyrizi) in treatment of patients with moderate to severe Crohn's disease

Patients treated with 600 mg or 1200 mg of risankizumab, an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit, met co-primary endpoints of clinical remission & endoscopic response at week 12 vs placebo (p<0.001 for each study)

Biospace Inc.